About Careers MedBlog Contact us

New Test to Predict Success of Stem Cell Transplants in Leukemia

by Dr. Trupti Shirole on December 24, 2014 at 6:03 PM
Font : A-A+

 New Test to Predict Success of Stem Cell Transplants in Leukemia

A study by researchers at the Icahn School of Medicine at Mount Sinai could reveal which patients will respond to treatment for graft versus host disease (GVHD), an often life-threatening complication of stem cell transplants (SCT) used to treat leukemia and other blood disorders.

Patients with fatal blood cancers like leukemia often require allogenic SCT for survival. Donor stem cells are transplanted to a recipient, but not without the risk of developing GVHD, a major cause of death after SCT. GVHD occurs when the transplanted donor cells (graft) attack the patient (host). However, the severity of symptoms severity does not accurately define how patients will respond to treatment and patients are often treated alike with high-dose steroids.


Researcher James L. M. Ferrara said, "High dose steroids are the only proven treatment for GVHD. Those with low-risk GVHD are often over-treated and face significant side-effects from treatment. Patients with high risk GVHD are undertreated and the GVHD progresses, often with fatal consequences. Our goal is to provide the right treatment for each patient. We hope to identify those patients at higher risk and design an aggressive intervention while tailoring a less-aggressive approach for those with low-risk."  

Dr. Ferrara and his team of researchers developed and tested this new scoring system with three distinct risk scores to predict the patient's response to GVHD treatment. The algorithm worked perfectly, with the cumulative incidence of non-relapse mortality significantly increasing as the GVHD score increased, and so the response rate to primary GVHD treatment decreased.

Dr. Ferrara said, "This new scoring system will help identify patient who may not respond to standard treatments, and may require an experimental and more aggressive approach. And it will also help guide treatment for patients with lower-risk GVHD who may be over-treated. This will allow us to personalize treatment at the onset of the disease. Future algorithms will prove increasingly useful to develop precision medicine for all SCT patients."

The study is published in the journal 'Lancet Haematology'.

Source: Medindia


Recommended Reading

Latest Genetics & Stem Cells News

 Stem Cell Treatment Resolves Perianal Fistulas in Crohn's Disease
Can stem cell therapy cure fistula? Yes, treatment with stem cells has had a success rate when used in perianal fistulas due to Crohn's Disease.
First Effective Preclinical Models for Most Common Genetic Cause of Leigh Syndrome
In zebrafish models of SURF1 mitochondrial disease, scientists have discovered drugs to prevent neurological decompensation.
Gene Therapy for Rare Eye Disease
New study advances intravitreal gene therapy platform to develop safe and effective therapies for visual loss in Usher Syndrome, rare disorder.
Autism-associated Mutation: New Insights
The study experiments shed light on a rare example of how autism-associated mutation could altered nuclear dynamics.
How Genomic Variants Could Help Diagnose Rare Genetic Disorders
A genotype-first approach to patient care involves selecting patients with specific genomic variants and then studying their traits and symptoms.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

New Test to Predict Success of Stem Cell Transplants in Leukemia Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests